# Bengt Glimelius

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5000661/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 321<br>papers | 29,492<br>citations | 14614<br>66<br>h-index | 5364<br>164<br>g-index |
| 324<br>all docs | 324<br>docs citations | 324<br>times ranked | 25812<br>citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Lowâ€dose aspirin use and colorectal cancer survival in 32,195 patientsâ€"A national cohort study. Cancer Medicine, 2023, 12, 315-324. | 1.3 | 6 |
| 2 | Prognostic role of tumour-infiltrating lymphocytes and macrophages in relation to MSI, CDX2 and BRAF status: a population-based study of metastatic colorectal cancer patients. British Journal of Cancer, 2022, 126, 48-56. | 2.9 | 8 |
| 3 | Survival Trends of Right- and Left-Sided Colon Cancer across Four Decades: A Norwegian Population-Based Study. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 342-351. | 1.1 | 7 |
| 4 | Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy. Journal of Clinical Oncology, 2022, 40, 1487-1496. | 0.8 | 6 |
| 5 | Mucinous rectal cancers: clinical features and prognosis in a population-based cohort. BJS Open, 2022, 6, . | 0.7 | 4 |
| 6 | KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer. Frontiers in Oncology, 2022, 12, 826073. | 1.3 | 15 |
| 7 | Current controversies in TNM for the radiological staging of rectal cancer and how to deal with them: results of a global online survey and multidisciplinary expert consensus. European Radiology, 2022, 32, 4991-5003. | 2.3 | 32 |
| 8 | Health-Related Quality of Life in Metastatic Colorectal Cancer Patients Treated with Curative Resection and/or Local Ablative Therapy or Systemic Therapy in the Finnish RAXO-Study. Cancers, 2022, 14, 1713. | 1.7 | 6 |
| 9 | Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer â€" The RAPIDO trial. Radiotherapy and Oncology, 2022, 171, 69-76. | 0.3 | 20 |
| 10 | TOSCAâ€"a delicious Swedish almond cake, an Italian opera and an Italian trial with important new data. Annals of Oncology, 2021, 32, 6-8. | 0.6 | 2 |
| 11 | Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2021, 22, 29-42. | 5.1 | 739 |
| 12 | Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes. , 2021, 5, 200-217. | | 0 |
| 13 | Interpreting the RAPIDO trial: factors to consider â€" Authors' reply. Lancet Oncology, The, 2021, 22, e90-e91. | 5.1 | 2 |
| 14 | The prognostic impact of the tumour stroma fraction: A machine learning-based analysis in 16 human solid tumour types. EBioMedicine, 2021, 65, 103269. | 2.7 | 25 |
| 15 | Completeness and accuracy of the registration of recurrences in the Swedish Colorectal Cancer Registry (SCRCR) and an update of recurrence risk in colon cancer. Acta OncolÃ³gica, 2021, 60, 842-849. | 0.8 | 16 |
| 16 | Does exercise intensity matter for fatigue during (neoâ€)adjuvant cancer treatment? The Physâ€Can randomized clinical trial. Scandinavian Journal of Medicine and Science in Sports, 2021, 31, 1144-1159. | 1.3 | 32 |
| 17 | Neoadjuvant rectal (NAR) score: Value evaluating the efficacy of neoadjuvant therapy and prognostic significance after surgery?. Radiotherapy and Oncology, 2021, 157, 70-77. | 0.3 | 10 |
| 18 | Pretreatment MRI in Primary Rectal Cancer as a Predictor for Oncological Outcomes After Surgery for Local Recurrence. Anticancer Research, 2021, 41, 2459-2465. | 0.5 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Clinicopathological factors associated with tumourâ€specific mutation detection in plasma of patients with <scp>RAS</scp>â€mutated or <scp>BRAF</scp>â€mutated metastatic colorectal cancer. International Journal of Cancer, 2021, 149, 1385-1397. | 2.3 | 10 |
| 20 | Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapyâ€"The Randomized NORDIC9-Study. Cancers, 2021, 13, 2604. | 1.7 | 13 |
| 21 | Accurate population-based model for individual prediction of colon cancer recurrence. Acta OncolÃ³gica, 2021, 60, 1241-1249. | 0.8 | 6 |
| 22 | Quality of life assessments in clinical practice using either the EORTC-QLQ-C30 or the SEIOQL-DW: a randomized study. Journal of Patient-Reported Outcomes, 2021, 5, 58. | 0.9 | 1 |
| 23 | Predictive Value of Neutrophils Count for Local Tumor Control After Chemoradiotherapy in Patients With Locally Advanced Pancreatic Carcinoma. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1022-1031. | 0.4 | 7 |
| 24 | Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone. Cancer Treatment Reviews, 2021, 98, 102218. | 3.4 | 33 |
| 25 | Investigation of Relation of Radiation Therapy Quality With Toxicity and Survival in LAP07 Phase 3 Trial for Locally Advanced Pancreatic Carcinoma. International Journal of Radiation Oncology Biology Physics, 2021, 110, 993-1002. | 0.4 | 6 |
| 26 | Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis. Clinical Colorectal Cancer, 2021, 20, 236-244. | 1.0 | 2 |
| 27 | A Comprehensive Evaluation of Associations Between Routinely Collected Staging Information and The Response to (Chemo)Radiotherapy in Rectal Cancer. Cancers, 2021, 13, 16. | 1.7 | 21 |
| 28 | The Immune Landscape of Colorectal Cancer. Cancers, 2021, 13, 5545. | 1.7 | 14 |
| 29 | hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. Cancers, 2021, 13, 5758. | 1.7 | 5 |
| 30 | Radiotherapy regimens for rectal cancer: long-term outcomes and health-related quality of life in the Stockholm III trial. BJS Open, 2021, 5, . | 0.7 | 3 |
| 31 | Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients. International Journal of Cancer, 2020, 146, 94-102. | 2.3 | 34 |
| 32 | No excess longâ€term mortality in stage Iâ€IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy. British Journal of Haematology, 2020, 188, 685-691. | 1.2 | 16 |
| 33 | Evaluation of the antibody response to the EBV proteome in EBVâ€associated classical Hodgkin lymphoma. International Journal of Cancer, 2020, 147, 608-618. | 2.3 | 15 |
| 34 | Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis. Acta OncolÃ³gica, 2020, 59, 417-426. | 0.8 | 22 |
| 35 | Beyond the NCCN Risk Factors in Colon Cancer: An Evaluation in a Swedish Population-Based Cohort. Annals of Surgical Oncology, 2020, 27, 1036-1045. | 0.7 | 18 |
| 36 | Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian study. Acta OncolÃ³gica, 2020, 59, 284-290. | 0.8 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Evaluation of the stage classification of anal cancer by the TNM 8th version versus the TNM 7th version. Acta OncolÃ³gica, 2020, 59, 1016-1023. | 0.8 | 8 |
| 38 | Recurrence Risk after Radical Colorectal Cancer Surgeryâ€"Less Than before, But How High Is It?. Cancers, 2020, 12, 3308. | 1.7 | 25 |
| 39 | O-19 Feasibility of switching to S-1 upon other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors. Annals of Oncology, 2020, 31, 239. | 0.6 | 2 |
| 40 | Adjuvant Chemotherapy in Elderly Colorectal Cancer Patients. Cancers, 2020, 12, 2289. | 1.7 | 14 |
| 41 | Moderators of the effect of psychosocial interventions on fatigue in women with breast cancer and men with prostate cancer: Individual patient data metaâ€analyses. Psycho-Oncology, 2020, 29, 1772-1785. | 1.0 | 11 |
| 42 | Prognostic Interactions between FAP+ Fibroblasts and CD8a+ T Cells in Colon Cancer. Cancers, 2020, 12, 3238. | 1.7 | 13 |
| 43 | Adjuvant chemotherapy in rectal cancer: state of the art and future perspectives. Current Opinion in Oncology, 2020, 32, 377-383. | 1.1 | 12 |
| 44 | ASO Author Reflections: Emerging Risk Factors in Colon Cancerâ€"End of the Line for Clinomics?. Annals of Surgical Oncology, 2020, 27, 1046-1047. | 0.7 | 0 |
| 45 | CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup. Frontiers in Oncology, 2020, 10, 8. | 1.3 | 35 |
| 46 | Effects and moderators of coping skills training on symptoms of depression and anxiety in patients with cancer: Aggregate data and individual patient data meta-analyses. Clinical Psychology Review, 2020, 80, 101882. | 6.0 | 7 |
| 47 | Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer â€" Results of the international randomized RAPIDO-trial. Radiotherapy and Oncology, 2020, 147, 75-83. | 0.3 | 132 |
| 48 | International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic. Radiotherapy and Oncology, 2020, 148, 213-215. | 0.3 | 65 |
| 49 | Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: The randomized RAPIDO trial.. Journal of Clinical Oncology, 2020, 38, 4006-4006. | 0.8 | 84 |
| 50 | ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma: Five year follow-up.. Journal of Clinical Oncology, 2020, 38, 4516-4516. | 0.8 | 20 |
| 51 | Feasibility of switching to S-1 after other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors.. Journal of Clinical Oncology, 2020, 38, 7037-7037. | 0.8 | 2 |
| 52 | Genetic overlap between autoimmune diseases and nonâ€Hodgkin lymphoma subtypes. Genetic Epidemiology, 2019, 43, 844-863. | 0.6 | 28 |
| 53 | Stroma-normalised vessel density predicts benefit from adjuvant fluorouracil-based chemotherapy in patients with stage II/III colon cancer. British Journal of Cancer, 2019, 121, 303-311. | 2.9 | 5 |
| 54 | Postoperative complications in relation to overall treatment time in patients with rectal cancer receiving neoadjuvant radiotherapy. British Journal of Surgery, 2019, 106, 1248-1256. | 0.1 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Consequences of a high incidence of microsatellite instability and BRAFâ€mutated tumors: A populationâ€based cohort of metastatic colorectal cancer patients. Cancer Medicine, 2019, 8, 3623-3635. | 1.3 | 40 |
| 56 | Determining the use of preoperative (chemo)radiotherapy in primary rectal cancer according to national and international guidelines. Radiotherapy and Oncology, 2019, 136, 106-112. | 0.3 | 10 |
| 57 | Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy. Annals of Oncology, 2019, 30, 1088-1095. | 0.6 | 65 |
| 58 | Lessons learned from the maturation of a cancer drug: oxaliplatin in colorectal cancer. Acta OncolÃ³gica, 2019, 58, 395-397. | 0.8 | 1 |
| 59 | Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 376-388. | 3.7 | 43 |
| 60 | Tumour regression after radiotherapy for rectal cancer â€“ Results from the randomised Stockholm III trial. Radiotherapy and Oncology, 2019, 135, 178-186. | 0.3 | 93 |
| 61 | Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study. Lancet Oncology, The, 2019, 20, 74-87. | 5.1 | 98 |
| 62 | Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591881835. | 1.4 | 13 |
| 63 | An audit of performance, interpretation, and influence of pretherapeutic MRI in rectal cancer: a Swedish population-based cohort study. Acta Radiologica, 2019, 60, 955-961. | 0.5 | 1 |
| 64 | The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 2019, 269, 520-529. | 2.1 | 189 |
| 65 | Genetically Determined Height and Risk of Non-hodgkin Lymphoma. Frontiers in Oncology, 2019, 9, 1539. | 1.3 | 6 |
| 66 | 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. Health Technology Assessment, 2019, 23, 1-88. | 1.3 | 20 |
| 67 | Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. British Journal of Cancer, 2018, 118, 947-954. | 2.9 | 30 |
| 68 | More than 1000 new manuscripts in 2017. Acta OncolÃ³gica, 2018, 57, 174-175. | 0.8 | 3 |
| 69 | Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Lancet Oncology, The, 2018, 19, e151-e160. | 5.1 | 51 |
| 70 | Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood, 2018, 131, 2541-2551. | 0.6 | 21 |
| 71 | How Long to Wait After Preoperative Radio(Chemo) Therapy to Perform Surgery?. , 2018, , 463-474. | | 0 |
| 72 | The PLIANT trial gives trustworthy data. Acta OncolÃ³gica, 2018, 57, 864-866. | 0.8 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Effects and moderators of psychosocial interventions on quality of life, and emotional and social function in patients with cancer: An individual patient data metaâ€analysis of 22 RCTs. Psycho-Oncology, 2018, 27, 1150-1161. | 1.0 | 74 |
| 74 | What treatments should be skipped or intensified in localized rectal cancer?. Future Oncology, 2018, 14, 313-318. | 1.1 | 1 |
| 75 | Short- and long-term risks of cardiovascular disease following radiotherapy in rectal cancer in four randomized controlled trials and a population-based register. Radiotherapy and Oncology, 2018, 126, 424-430. | 0.3 | 10 |
| 76 | Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review. European Journal of Cancer, 2018, 96, 115-124. | 1.3 | 2 |
| 77 | 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncology, The, 2018, 19, 562-578. | 5.1 | 133 |
| 78 | Quality of life and cost effectiveness in a randomized trial of patients with colorectal cancer and peritoneal metastases. European Journal of Surgical Oncology, 2018, 44, 983-990. | 0.5 | 12 |
| 79 | Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. British Journal of Cancer, 2018, 118, 1084-1088. | 2.9 | 9 |
| 80 | U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden. Acta OncolÃ³gica, 2018, 57, 187-194. | 0.8 | 52 |
| 81 | Neoadjuvant Therapy in Rectal Cancer Patients With Clinical Stage II to III Across European Countries: Variations and Outcomes. Clinical Colorectal Cancer, 2018, 17, e129-e142. | 1.0 | 20 |
| 82 | Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx<sup>Â®</sup>): a placebo-controlled randomised phase II study (PLIANT). Acta OncolÃ³gica, 2018, 57, 393-402. | 0.8 | 69 |
| 83 | Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 395-405. | 1.4 | 10 |
| 84 | Administration of adjuvant chemotherapy for stage <scp>IIâ€III</scp> colon cancer patients: An European populationâ€based study. International Journal of Cancer, 2018, 142, 1480-1489. | 2.3 | 39 |
| 85 | NORDIC9: A randomized phase II trial comparing first-line palliative full-dose monotherapy (S-1) with reduced dose-combination therapy (SOx) in older and frail patients with metastatic colorectal cancer (mCRC). Annals of Oncology, 2018, 29, viii151. | 0.6 | 1 |
| 86 | Forty-five years in oncology, 25 years with Acta Oncologica. Acta OncolÃ³gica, 2018, 57, 1593-1598. | 0.8 | 3 |
| 87 | SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. British Journal of Cancer, 2018, 119, 1332-1338. | 2.9 | 19 |
| 88 | Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for WaldenstrÃ¶m macroglobulinemia. Nature Communications, 2018, 9, 4182. | 5.8 | 15 |
| 89 | Do we make progress in elderly patients with metastatic colorectal cancer?. Acta OncolÃ³gica, 2018, 57, 1422-1426. | 0.8 | 3 |
| 90 | Recurrence Risk After Up-to-Date Colon Cancer Staging, Surgery, and Pathology: Analysis of the Entire Swedish Population. Diseases of the Colon and Rectum, 2018, 61, 1016-1025. | 0.7 | 127 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Preoperative radiotherapy or chemoradiotherapy in rectal cancer â€“ Is survival improved? An update of the â€œNordicâ€•LARC study in non-resectable cancers. Radiotherapy and Oncology, 2018, 127, 392-395. | 0.3 | 10 |
| 92 | Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. European Journal of Cancer, 2018, 100, 35-45. | 1.3 | 29 |
| 93 | HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Research, 2018, 78, 4086-4096. | 0.4 | 34 |
| 94 | Stage distribution utilizing magnetic resonance imaging in an unselected population of primary rectal cancers. European Journal of Surgical Oncology, 2018, 44, 1858-1864. | 0.5 | 5 |
| 95 | Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome. British Journal of Cancer, 2018, 118, 1609-1616. | 2.9 | 47 |
| 96 | Somatic Ephrin Receptor Mutations Are Associated with Metastasis in Primary Colorectal Cancer. Cancer Research, 2017, 77, 1730-1740. | 0.4 | 29 |
| 97 | Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncology, The, 2017, 18, 336-346. | 5.1 | 447 |
| 98 | Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. Nature Communications, 2017, 8, 14175. | 5.8 | 75 |
| 99 | On a prolonged interval between rectal cancer (chemo)radiotherapy and surgery. Upsala Journal of Medical Sciences, 2017, 122, 1-10. | 0.4 | 27 |
| 100 | Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study. British Journal of Cancer, 2017, 116, 1271-1278. | 2.9 | 55 |
| 101 | Need for adjuvant chemotherapy after colon cancer surgery â€“ has it decreased?. Acta OncolÃ³gica, 2017, 56, 629-633. | 0.8 | 6 |
| 102 | Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status. European Journal of Cancer, 2017, 81, 26-35. | 1.3 | 13 |
| 103 | Development of anxiety, depression and health-related quality of life in oncology patients without initial symptoms according to the Hospital Anxiety and Depression Scale â€“ a comparative study. Acta OncolÃ³gica, 2017, 56, 1094-1102. | 0.8 | 10 |
| 104 | Different functions of AKT1 and AKT2 in molecular pathways, cell migration and metabolism in colon cancer cells. International Journal of Oncology, 2017, 50, 5-14. | 1.4 | 53 |
| 105 | Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer. British Journal of Cancer, 2017, 117, 1478-1485. | 2.9 | 118 |
| 106 | A pathology atlas of the human cancer transcriptome. Science, 2017, 357, . | 6.0 | 2,570 |
| 107 | Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. Lupus Science and Medicine, 2017, 4, e000187. | 1.1 | 15 |
| 108 | What conclusions can be drawn from the Stockholm III rectal cancer trial in the era of watch and wait?. Acta OncolÃ³gica, 2017, 56, 1139-1142. | 0.8 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Risk of second primary cancer in patients treated with radiotherapy for rectal cancer. British Journal of Surgery, 2017, 104, 278-287. | 0.1 | 43 |
| 110 | Associations of defect mismatch repair genes with prognosis and heredity in sporadic colorectal cancer. European Journal of Surgical Oncology, 2017, 43, 311-321. | 0.5 | 14 |
| 111 | Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9. BMC Cancer, 2017, 17, 548. | 1.1 | 13 |
| 112 | Prognostic factors in patients with loco-regionally advanced gastric cancer. World Journal of Surgical Oncology, 2017, 15, 172. | 0.8 | 11 |
| 113 | Reply to C.F. Hess et al. Journal of Clinical Oncology, 2017, 35, 374-374. | 0.8 | 0 |
| 114 | High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer. PLoS ONE, 2017, 12, e0182512. | 1.1 | 27 |
| 115 | Does shared decision making exist in oncologic practice?. Acta OncolÃ³gica, 2016, 55, 125-128. | 0.8 | 4 |
| 116 | Any progress in pancreatic cancer?. Acta OncolÃ³gica, 2016, 55, 255-258. | 0.8 | 2 |
| 117 | PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer. Annals of Oncology, 2016, 27, 1557-1565. | 0.6 | 64 |
| 118 | Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib. JAMA - Journal of the American Medical Association, 2016, 315, 1844. | 3.8 | 801 |
| 119 | Reply to D.J. Sargent et al. Journal of Clinical Oncology, 2016, 34, 3713-3714. | 0.8 | 0 |
| 120 | Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. Carcinogenesis, 2016, 37, 852-857. | 1.3 | 15 |
| 121 | Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP). British Journal of Cancer, 2016, 115, 281-289. | 2.9 | 61 |
| 122 | Two countries â€“ Two treatment strategies for rectal cancer. Radiotherapy and Oncology, 2016, 121, 357-363. | 0.3 | 48 |
| 123 | What is most relevant in preoperative rectal cancer chemoradiotherapy â€“ the chemotherapy, the radiation dose or the timing to surgery?. Acta OncolÃ³gica, 2016, 55, 1381-1385. | 0.8 | 9 |
| 124 | ESPAC-4: A multicenter, international, open label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP), versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. Pancreatology, 2016, 16, S63. | 0.5 | 20 |
| 125 | Lymphovascular and perineural invasion in stage II rectal cancer: a report from the Swedish colorectal cancer registry. Acta OncolÃ³gica, 2016, 55, 1418-1424. | 0.8 | 49 |
| 126 | Tell all the good news as soon as possible. Acta OncolÃ³gica, 2016, 55, 1067-1068. | 0.8 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Image analysis-derived metrics of histomorphological complexity predicts prognosis and treatment response in stage II-III colon cancer. Scientific Reports, 2016, 6, 36149. | 1.6 | 23 |
| 128 | Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. Nature Communications, 2016, 7, 10933. | 5.8 | 94 |
| 129 | Impact of pre-treatment patient-related selection parameters on outcome in rectal cancer. European Journal of Surgical Oncology, 2016, 42, 1667-1673. | 0.5 | 8 |
| 130 | Detection of Biomarkers with Solid-Phase Proximity Ligation Assay in Patients with Colorectal Cancer. Translational Oncology, 2016, 9, 251-255. | 1.7 | 5 |
| 131 | Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. Human Molecular Genetics, 2016, 25, 1663-1676. | 1.4 | 52 |
| 132 | Should the Benefit of Adjuvant Chemotherapy in Colon Cancer Be Re-Evaluated?. Journal of Clinical Oncology, 2016, 34, 1297-1299. | 0.8 | 65 |
| 133 | Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial. European Journal of Cancer, 2016, 53, 155-162. | 1.3 | 123 |
| 134 | TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer. Oncotarget, 2016, 7, 59441-59457. | 0.8 | 7 |
| 135 | Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer. Oncotarget, 2016, 7, 75013-75022. | 0.8 | 61 |
| 136 | Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer. British Journal of Surgery, 2015, 102, 972-978. | 0.1 | 173 |
| 137 | Whatâ€™s new about Acta Oncologica for 2016?. Acta OncolÃ³gica, 2015, 54, 1703-1705. | 0.8 | 1 |
| 138 | Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab. International Journal of Cancer, 2015, 137, 2470-2477. | 2.3 | 8 |
| 139 | Time trends, improvements and national auditing of rectal cancer management over an 18â€year period. Colorectal Disease, 2015, 17, O168-79. | 0.7 | 80 |
| 140 | High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort. PLoS ONE, 2015, 10, e0131046. | 1.1 | 91 |
| 141 | A genome-wide association study of marginal zone lymphoma shows association to the HLA region. Nature Communications, 2015, 6, 5751. | 5.8 | 58 |
| 142 | Risk of recurrence in patients with colon cancer stage II and III: A systematic review and meta-analysis of recent literature. Acta OncolÃ³gica, 2015, 54, 5-16. | 0.8 | 270 |
| 143 | <sup>15</sup>O-Water PET Study of the Effect of Imatinib, a Selective Platelet-Derived Growth Factor Receptor Inhibitor, Versus Anakinra, an IL-1R Antagonist, on Water-Perfusable Tissue Fraction in Colorectal Cancer Metastases. Journal of Nuclear Medicine, 2015, 56, 1144-1149. | 2.8 | 17 |
| 144 | Is the benefit of oxaliplatin in rectal cancer clinically relevant?. Lancet Oncology, The, 2015, 16, 883-885. | 5.1 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo)therapy: A meta-analysis of randomized trials comparing surgeryÂÂ±Âa fluoropyrimidine and surgeryÂ+Âa fluoropyrimidineÂÂ±Âoxaliplatin. European Journal of Surgical Oncology, 2015, 41, 713-723. | 0.5 | 106 |
| 146 | Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. Annals of Oncology, 2015, 26, 1936-1941. | 0.6 | 24 |
| 147 | Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer. BMC Cancer, 2015, 15, 125. | 1.1 | 35 |
| 148 | Adjuvant chemotherapy for patients with rectal cancer â€“ will the controversy be resolved?. Acta OncolÃ³gica, 2015, 54, 433-436. | 0.8 | 6 |
| 149 | Is England closing the international gap in cancer survival?. British Journal of Cancer, 2015, 113, 848-860. | 2.9 | 97 |
| 150 | Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Annals of Oncology, 2015, 26, 696-701. | 0.6 | 302 |
| 151 | Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Annals of Oncology, 2015, 26, 463-476. | 0.6 | 327 |
| 152 | Toxicity and quality of life data from SCOT: An international phase III randomized (1:1) noninferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy.. Journal of Clinical Oncology, 2015, 33, 3514-3514. | 0.8 | 5 |
| 153 | Prognosis model for overall survival in locally advanced unresecable pancreatic carcinoma: An ancillary study of the LAP 07 trial.. Journal of Clinical Oncology, 2015, 33, 235-235. | 0.8 | 1 |
| 154 | Prognostic effect of a single nucleotide polymorphism (SNP) in MIR608 in patients with high-risk locally advanced rectal cancer (LARC): Results of the EXPERT-C trial.. Journal of Clinical Oncology, 2015, 33, 581-581. | 0.8 | 1 |
| 155 | C-reactive protein and interleukin-6 as markers of systemic inflammatory response and as prognostic factors for metastatic colorectal cancer. Data from the randomized phase III NORDIC-VII study.. Journal of Clinical Oncology, 2015, 33, 3548-3548. | 0.8 | 0 |
| 156 | Evaluation of Cancer Stem Cell Markers CD133, CD44, CD24: Association with AKT Isoforms and Radiation Resistance in Colon Cancer Cells. PLoS ONE, 2014, 9, e94621. | 1.1 | 177 |
| 157 | The 50-year anniversary of Acta Oncologica. Acta OncolÃ³gica, 2014, 53, 1-2. | 0.8 | 10 |
| 158 | Acta Oncologica and a new generation of scientists in oncology. Acta OncolÃ³gica, 2014, 53, 849-851. | 0.8 | 3 |
| 159 | Anal carcinoma â€“ Survival and recurrence in a large cohort of patients treated according to Nordic guidelines. Radiotherapy and Oncology, 2014, 113, 352-358. | 0.3 | 49 |
| 160 | Preoperative treatment selection in rectal cancer: AÂpopulation-based cohort study. European Journal of Surgical Oncology, 2014, 40, 1782-1788. | 0.5 | 19 |
| 161 | A comprehensive evaluation of the role of genetic variation in follicular lymphoma survival. BMC Medical Genetics, 2014, 15, 113. | 2.1 | 17 |
| 162 | Optimal Time Intervals between Pre-Operative Radiotherapy or Chemoradiotherapy and Surgery in Rectal Cancer?. Frontiers in Oncology, 2014, 4, 50. | 1.3 | 43 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Adjuvant chemotherapy for rectal cancer. Lancet Oncology, The, 2014, 15, e194-e195. | 5.1 | 4 |
| 164 | The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis. Pharmacogenomics Journal, 2014, 14, 424-431. | 0.9 | 36 |
| 165 | EURECCA consensus conference highlights about rectal cancer clinical management: The radiation oncologistâ€™s expert review. Radiotherapy and Oncology, 2014, 110, 195-198. | 0.3 | 61 |
| 166 | EURECCA colorectal: Multidisciplinary management: European consensus conference colon & rectum. European Journal of Cancer, 2014, 50, 1.e1-1.e34. | 1.3 | 349 |
| 167 | Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). European Journal of Cancer, 2014, 50, 2983-2993. | 1.3 | 56 |
| 168 | Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nature Genetics, 2014, 46, 1233-1238. | 9.4 | 147 |
| 169 | Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. American Journal of Human Genetics, 2014, 95, 462-471. | 2.6 | 96 |
| 170 | TP53 Mutational Status and Cetuximab Benefit in Rectal Cancer: 5-Year Results of the EXPERT-C Trial. Journal of the National Cancer Institute, 2014, 106, . | 3.0 | 46 |
| 171 | Comparison of ColoPrint risk classification with clinical risk in the prospective PARSC trial.. Journal of Clinical Oncology, 2014, 32, 3562-3562. | 0.8 | 1 |
| 172 | Panex: A pooled analysis of EXPERT and EXPERT-C, two trials of neoadjuvant chemotherapy (NACT) and chemoradiotherapy (CRT) in high-risk locally advanced rectal cancer (LARC).. Journal of Clinical Oncology, 2014, 32, 3575-3575. | 0.8 | 7 |
| 173 | Impact of chemoradiotherapy (CRT) on local control and time without treatment in patients with locally advanced pancreatic cancer (LAPC) included in the international phase III LAP 07 study.. Journal of Clinical Oncology, 2014, 32, 4001-4001. | 0.8 | 25 |
| 174 | Comparison of ColoPrint risk classification with clinical risk in the prospective PARSC trial.. Journal of Clinical Oncology, 2014, 32, 465-465. | 0.8 | 2 |
| 175 | RAS mutations in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab (C) in MRI-defined, high-risk rectal cancer (RC).. Journal of Clinical Oncology, 2014, 32, 489-489. | 0.8 | 3 |
| 176 | Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study. PLoS ONE, 2014, 9, e87746. | 1.1 | 18 |
| 177 | Relationship of RAS and TP53 predictive value for cetuximab (C) benefit: Results of the EXPERT-C trial.. Journal of Clinical Oncology, 2014, 32, 447-447. | 0.8 | 0 |
| 178 | Outcome after liver transplantation compared with chemotherapy in colorectal cancer patients with nonresectable liver-only disease.. Journal of Clinical Oncology, 2014, 32, 531-531. | 0.8 | 0 |
| 179 | FCÎ³RIIa and FCÎ³RIIIa polymorphisms (SNPs) and cetuximab (C) benefit in the EXPERT-C trial.. Journal of Clinical Oncology, 2014, 32, 3573-3573. | 0.8 | 0 |
| 180 | Digitalized multiparametric analyses of tumor stroma for identification of low perivascular PDGFBR expression and low vessel density as independent prognosis markers for stage IV CRC.. Journal of Clinical Oncology, 2014, 32, e14525-e14525. | 0.8 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Prognosis model for overall survival in locally advanced pancreatic cancer (LAPC): An ancillary study of the LAP 07 trial.. Journal of Clinical Oncology, 2014, 32, 4024-4024. | 0.8 | 1 |
| 182 | Benefit of EGFR-inhibition therapy for metastatic colorectal cancer patients with KRAS-mutated tumors and high plasma TIMP-1 level: Results from the NORDIC VII study.. Journal of Clinical Oncology, 2014, 32, 3590-3590. | 0.8 | 0 |
| 183 | Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer â€" the RAPIDO trial. BMC Cancer, 2013, 13, 279. | 1.1 | 237 |
| 184 | Target Volume Definition in Rectal Cancer: What Is the Best Imaging Modality?. Current Colorectal Cancer Reports, 2013, 9, 116-125. | 1.0 | 0 |
| 185 | Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2013, 14, 1208-1215. | 5.1 | 1,017 |
| 186 | Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2013, 24, vi81-vi88. | 0.6 | 833 |
| 187 | Adjuvant chemotherapy. European Journal of Cancer, Supplement, 2013, 11, 72-79. | 2.2 | 1 |
| 188 | Integrated peripheral boost in preoperative radiotherapy for the locally most advanced non-resectable rectal cancer patients. Acta OncolÃ³gica, 2013, 52, 528-537. | 0.8 | 27 |
| 189 | Patients with rectal cancer receiving adjuvant chemotherapy have an increased survival: a population-based longitudinal study. Annals of Oncology, 2013, 24, 160-165. | 0.6 | 67 |
| 190 | Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer. Annals of Oncology, 2013, 24, 2354-2360. | 0.6 | 65 |
| 191 | 50 years with Acta Oncologica. Acta OncolÃ³gica, 2013, 52, 1-2. | 0.8 | 7 |
| 192 | Population-based data from the Swedish Colon Cancer Registry. British Journal of Surgery, 2013, 100, 1100-1107. | 0.1 | 91 |
| 193 | Neo-adjuvant radiotherapy in rectal cancer. World Journal of Gastroenterology, 2013, 19, 8489. | 1.4 | 51 |
| 194 | HENT1 tumor levels to predict survival of pancreatic ductal adenocarcinoma patients who received adjuvant gemcitabine and adjuvant 5FU on the ESPAC trials.. Journal of Clinical Oncology, 2013, 31, 4006-4006. | 0.8 | 15 |
| 195 | Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.. Journal of Clinical Oncology, 2013, 31, LBA4003-LBA4003. | 0.8 | 31 |
| 196 | Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.. Journal of Clinical Oncology, 2013, 31, LBA4003-LBA4003. | 0.8 | 61 |
| 197 | Plasma levels of TIMP-1 in chemo-naive patients with metastatic colorectal cancer treated with first-line FLOX with or without cetuximab: Results from the Nordic VII Study.. Journal of Clinical Oncology, 2013, 31, 392-392. | 0.8 | 0 |
| 198 | Plasma TIMP-1 in patients with metastatic colorectal cancer treated with first-line oxaliplatin-based therapy with or without cetuximab: Results from the Nordic VII study.. Journal of Clinical Oncology, 2013, 31, e14710-e14710. | 0.8 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Prognostic significance of tumor stromal and epithelial claudin 2 in metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 3597-3597. | 0.8 | 0 |
| 200 | Tumor perivascular PDGFBR as an independent prognostic factor in metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 3571-3571. | 0.8 | 0 |
| 201 | A Meta-Analysis Of Hodgkin Lymphoma Reveals 19p13.3 (TCF3) As a Novel Susceptibility Loc. Blood, 2013, 122, 626-626. | 0.6 | 0 |
| 202 | Multidisciplinary treatment of patients with rectal cancer: Development during the past decades and plans for the future. Upsala Journal of Medical Sciences, 2012, 117, 225-236. | 0.4 | 38 |
| 203 | Lower treatment intensity and poorer survival in metastatic colorectal cancer patients who live alone. British Journal of Cancer, 2012, 107, 189-194. | 2.9 | 41 |
| 204 | Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study. Journal of Clinical Oncology, 2012, 30, 1755-1762. | 0.8 | 482 |
| 205 | ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Annals of Oncology, 2012, 23, 2479-2516. | 0.6 | 1,233 |
| 206 | Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C). Journal of Clinical Oncology, 2012, 30, 1620-1627. | 0.8 | 357 |
| 207 | Metastatic colorectal cancer: Current treatment and future options for improved survivalMedical approach â€“ present status. Scandinavian Journal of Gastroenterology, 2012, 47, 296-314. | 0.6 | 53 |
| 208 | EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results.. Journal of Clinical Oncology, 2012, 30, 3508-3508. | 0.8 | 27 |
| 209 | Maintenance therapy with biweekly cetuximab (C) in the first-line treatment of metastatic colorectal cancer (mCRC): The NORDIC 7.5 study (NCT00660582), by the Nordic Colorectal Cancer Biomodulation Group.. Journal of Clinical Oncology, 2012, 30, 3538-3538. | 0.8 | 2 |
| 210 | Prognostic impact of preoperative plasma tissue inhibitor of metalloproteinase 1 (pTIMP-1) in colorectal cancer (CRC) patients (Pts): A pooled analysis of 1,024 stage II/III pts.. Journal of Clinical Oncology, 2012, 30, 3576-3576. | 0.8 | 1 |
| 211 | International expertsâ€™ panel for the development of guidelines for the definition of time to event endpoints in clinical trials (DATECAN project): Results for pancreatic cancer.. Journal of Clinical Oncology, 2012, 30, 4053-4053. | 0.8 | 1 |
| 212 | ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 IntergroupÂ randomized phase III clinical trial.. Journal of Clinical Oncology, 2012, 30, 8002-8002. | 0.8 | 38 |
| 213 | The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint.. Journal of Clinical Oncology, 2012, 30, 678-678. | 0.8 | 5 |
| 214 | Plasma concentrations of YKL-40 in chemo-naive patients with metastatic colorectal cancer treated with FLOX with or without cetuximab: Results from the NORDIC VII study.. Journal of Clinical Oncology, 2012, 30, 3548-3548. | 0.8 | 0 |
| 215 | The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer patients using ColoPrint.. Journal of Clinical Oncology, 2012, 30, TPS10632-TPS10632. | 0.8 | 1 |
| 216 | The impact of TP53 mutation on high-risk rectal cancer patients treated within the EXPERT-C trial, a randomized phase II study of neoadjuvant oxaliplatin/capecitabine (CAPOX) and chemoradiation (CRT) with or without cetuximab.. Journal of Clinical Oncology, 2012, 30, e14088-e14088. | 0.8 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Which rectal cancers are locally advanced?. Oncology, 2012, 26, 743, 746, 751-2. | 0.4 | 0 |
| 218 | Life of Pi. Acta OncolÃ³gica, 2011, 50, 1139-1141. | 0.8 | 2 |
| 219 | And they lived happily ever afterâ€¦ The marriage of Nordic Association for Clinical Physics and Acta Oncologica. Acta OncolÃ³gica, 2011, 50, 835-837. | 0.8 | 8 |
| 220 | Survival endpoints in colorectal cancer and the effect of second primary other cancer on disease free survival. BMC Cancer, 2011, 11, 438. | 1.1 | 51 |
| 221 | Late Patient-Reported Toxicity After Preoperative Radiotherapy or Chemoradiotherapy in Nonresectable Rectal Cancer: Results From a Randomized Phase III Study. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1017-1024. | 0.4 | 87 |
| 222 | Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics Journal, 2011, 11, 61-71. | 0.9 | 108 |
| 223 | Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology. Annals of Oncology, 2011, 22, 1717-1725. | 0.6 | 49 |
| 224 | A new volume of Acta Oncologica. Acta OncolÃ³gica, 2011, 50, 3-5. | 0.8 | 4 |
| 225 | Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. British Journal of Surgery, 2010, 97, 580-587. | 0.1 | 233 |
| 226 | A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). Nature Genetics, 2010, 42, 1126-1130. | 9.4 | 177 |
| 227 | Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2010, 21, v82-v86. | 0.6 | 86 |
| 228 | Adjuvant chemotherapy in rectal cancerâ€"an issue or a nonissue?. Annals of Oncology, 2010, 21, 1739-1741. | 0.6 | 19 |
| 229 | A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer. Annals of Oncology, 2010, 21, 1020-1026. | 0.6 | 22 |
| 230 | Rectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2009, 20, iv54-iv56. | 0.6 | 56 |
| 231 | Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer, 2009, 115, 4679-4687. | 2.0 | 128 |
| 232 | Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiotherapy and Oncology, 2009, 92, 148-163. | 0.3 | 275 |
| 233 | Risk of EBV-Positive Hodgkin Lymphoma Varies Over 30-Fold by HLA Class I Genotype and History of Infectious Mononucleosis.. Blood, 2009, 114, 269-269. | 0.6 | 0 |
| 234 | Authors' reply: Late gastrointestinal disorders after rectal cancer surgery with and without preoperative radiation therapy (Br J Surg 2008; 95: 206â€"213). British Journal of Surgery, 2008, 95, 803-803. | 0.1 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Health-related quality of life and distress in cancer patients: results from a large randomised study. British Journal of Cancer, 2008, 99, 1975-1983. | 2.9 | 49 |
| 236 | Short-course preoperative radiotherapy with delayed surgery in rectal cancer â€“ A retrospective study. Radiotherapy and Oncology, 2008, 87, 343-349. | 0.3 | 199 |
| 237 | Randomized Phase III Study Comparing Preoperative Radiotherapy With Chemoradiotherapy in Nonresectable Rectal Cancer. Journal of Clinical Oncology, 2008, 26, 3687-3694. | 0.8 | 412 |
| 238 | A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. Annals of Oncology, 2008, 19, 909-914. | 0.6 | 40 |
| 239 | The â€˜goodâ€™, the â€˜badâ€™, and the â€˜uglyâ€™ rectal cancers. Acta OncolÃ³gica, 2008, 47, 5-8. | 0.8 | 91 |
| 240 | Chemotherapy in Addition to Preoperative Radiotherapy in Locally Advanced Rectal Cancer â€“ A Systematic Overview. Reviews on Recent Clinical Trials, 2008, 3, 204-211. | 0.4 | 32 |
| 241 | Individual Psychosocial Support for Breast Cancer Patients. Cancer Nursing, 2007, 30, E10-E19. | 0.7 | 83 |
| 242 | Late adverse effects of radiation therapy for rectal cancer â€“ a systematic overview. Acta OncolÃ³gica, 2007, 46, 504-516. | 0.8 | 195 |
| 243 | Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. Journal of Clinical Oncology, 2007, 25, LBA5-LBA5. | 0.8 | 54 |
| 244 | Authors' reply: Radiological findings do not support lateral residual tumour as a major cause of local recurrence of rectal cancer (Br J Surg 2006; 93: 113â€“119). British Journal of Surgery, 2006, 93, 507-507. | 0.1 | 0 |
| 245 | Late adverse effects of short-course preoperative radiotherapy in rectal cancer. British Journal of Surgery, 2006, 93, 1519-1525. | 0.1 | 193 |
| 246 | A comparative study of proliferation-associated parameters in b-cell non-hodgkin lymphoma. Hematological Oncology, 2006, 9, 287-298. | 0.8 | 15 |
| 247 | Number of patients potentially eligible for proton therapy. Acta OncolÃ³gica, 2005, 44, 836-849. | 0.8 | 80 |
| 248 | RESPONSE: Re: Sun Exposure and Mortality From Melanoma. Journal of the National Cancer Institute, 2005, 97, 1160-1161. | 3.0 | 1 |
| 249 | Adjuvant chemotherapy in colorectal cancer: A joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta OncolÃ³gica, 2005, 44, 904-912. | 0.8 | 94 |
| 250 | Benefit-Risk Assessment of Irinotecan in Advanced Colorectal Cancer. Drug Safety, 2005, 28, 417-433. | 1.4 | 26 |
| 251 | Multicenter Phase II Study of Nordic Fluorouracil and Folinic Acid Bolus Schedule Combined With Oxaliplatin As First-Line Treatment of Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2004, 22, 31-38. | 0.8 | 76 |
| 252 | The potential for improved outcome in patients with hepatic metastases from colon cancer: a population-based study. European Journal of Surgical Oncology, 2004, 30, 834-841. | 0.5 | 44 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Changing strategy for rectal cancer is associated with improved outcome. British Journal of Surgery, 2003, 86, 379-384. | 0.1 | 158 |
| 254 | Acta Oncologicaâ€"Greater Attractiveness. Acta OncolÃ³gica, 2003, 42, 799-799. | 0.8 | 4 |
| 255 | Radiotherapy in rectal cancer. British Medical Bulletin, 2002, 64, 141-157. | 2.7 | 28 |
| 256 | Oncology in the Nordic Countries: The Role of Acta Oncologica?. Acta OncolÃ³gica, 2002, 41, 3-5. | 0.8 | 11 |
| 257 | Swedish Cancer Society Radiation Therapy Research Investigation. Acta OncolÃ³gica, 2002, 41, 596-603. | 0.8 | 13 |
| 258 | Sensitizing and Protective Substances in Radiation Therapy and Predictive Assays. Acta OncolÃ³gica, 2002, 41, 615-622. | 0.8 | 7 |
| 259 | Radiation Therapy Through Activation of Stable Nuclides. Acta OncolÃ³gica, 2002, 41, 629-634. | 0.8 | 18 |
| 260 | Therapy with Radiopharmaceuticals. Acta OncolÃ³gica, 2002, 41, 623-628. | 0.8 | 23 |
| 261 | Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. Annals of Oncology, 2002, 13, 1868-1873. | 0.6 | 28 |
| 262 | Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer. New England Journal of Medicine, 2001, 345, 638-646. | 13.9 | 3,840 |
| 263 | The Swedish Council on Technology Assessment in Health Care (SBU) Systematic Overview of Chemotherapy Effects in Some Major Tumour Types - Summary and Conclusions. Acta OncolÃ³gica, 2001, 40, 135-154. | 0.8 | 35 |
| 264 | Non-melanoma skin cancer may be a marker of poor prognosis in patients with non-Hodgkin's lymphoma. , 2000, 85, 639-642. | | 34 |
| 265 | Implementation of pencil kernel and depth penetration algorithms for treatment planning of proton beams. Physics in Medicine and Biology, 2000, 45, 9-27. | 1.6 | 84 |
| 266 | Is History of Squamous-Cell Skin Cancer a Marker of Poor Prognosis in Patients with Cancer?. Annals of Internal Medicine, 1999, 131, 655. | 2.0 | 26 |
| 267 | Perioperative Radiotherapy in Rectal Cancer. Acta OncolÃ³gica, 1999, 38, 23-32. | 0.8 | 36 |
| 268 | Epstein-Barr Virus Distribution in Hodgkin's Disease in an Unselected Swedish Population. Acta OncolÃ³gica, 1999, 38, 425-429. | 0.8 | 57 |
| 269 | Potential Gains Using High-Energy Protons for Therapy of Malignant Tumours. Acta OncolÃ³gica, 1999, 38, 137-145. | 0.8 | 36 |
| 270 | Chemotherapy in the treatment of cancer of the pancreas. Journal of Hepato-Biliary-Pancreatic Surgery, 1998, 5, 235-241. | 2.0 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | Preoperative irradiation affects functional results after surgery for rectal cancer. Diseases of the Colon and Rectum, 1998, 41, 543-549. | 0.7 | 419 |
| 272 | Bolus injection (2â€“4min) versus short-term (10â€“20min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. European Journal of Cancer, 1998, 34, 674-678. | 1.3 | 63 |
| 273 | Evaluation of Clinical Benefit of Chemotherapy in Patients with Upper Gastrointestinal Cancer. Acta OncolÃ³gica, 1998, 37, 651-659. | 0.8 | 25 |
| 274 | The Swedish National Care Programme for Anal Carcinoma: Implementation and Overall Results. Acta OncolÃ³gica, 1998, 37, 25-32. | 0.8 | 23 |
| 275 | Methylâ€GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease: a prospective study. European Journal of Haematology, 1998, 60, 166-171. | 1.1 | 11 |
| 276 | Improved Survival with Preoperative Radiotherapy in Resectable Rectal Cancer. New England Journal of Medicine, 1997, 336, 980-987. | 13.9 | 2,420 |
| 277 | [<sup>18</sup>F] FDG PET in Gastric Non-Hodgkin's Lymphoma. Acta OncolÃ³gica, 1997, 36, 577-584. | 0.8 | 38 |
| 278 | Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Annals of Oncology, 1997, 8, 163-168. | 0.6 | 735 |
| 279 | Short-term preoperative radiotherapy results in down-staging of rectal cancer: a study of 1316 patients. Radiotherapy and Oncology, 1997, 43, 133-137. | 0.3 | 152 |
| 280 | Pregnancy and risk of non-Hodgkin's lymphoma: A prospective study. , 1997, 70, 155-158. | | 38 |
| 281 | Patients suffering from both Hodgkin's disease and non-Hodgkin's lymphoma: A clinico-pathological and immuno-histochemical population-based study of 32 patients. , 1997, 71, 510-516. | | 25 |
| 282 | Lack of correlation between EBV serology and presence of EBV in the Hodgkin and Reed-Sternberg cells of patients with Hodgkin's disease. , 1997, 72, 394-397. | | 35 |
| 283 | Infradiaphragmatic Hodgkin's disease: the Swedish National Care Programme experience. European Journal of Haematology, 1997, 59, 31-37. | 1.1 | 12 |
| 284 | Patients suffering from both Hodgkin's disease and non-Hodgkin's lymphoma: A clinico-pathological and immuno-histochemical population-based study of 32 patients. , 1997, 71, 510. | | 1 |
| 285 | Ultraviolet Light and Non-Hodgkin's Lymphoma. Acta OncolÃ³gica, 1996, 35, 655-657. | 0.8 | 21 |
| 286 | Anxiety, Depression and Worry in Gastrointestinal Cancer Patients Attending Medical Follow-Up Control Visits. Acta OncolÃ³gica, 1996, 35, 411-416. | 0.8 | 22 |
| 287 | Methyl-Gag, Ifosfamide, Methotrexate and Etoposide (Mime) as Salvage Therapy for Non-Hodgkin's Lymphomasa Swedish national prospective study. Acta OncolÃ³gica, 1996, 35, 165-170. | 0.8 | 12 |
| 288 | Different Intravenous Administration Techniques for 5-Fluorouracil Pharmacokinetics and Pharmacodynamic Effects. Acta OncolÃ³gica, 1996, 35, 207-212. | 0.8 | 36 |

| # | Article | IF | Citations |
|---|---|---|---|
| 289 | Maternal and perinatal risk factors for childhood brain tumors (Sweden). Cancer Causes and Control, 1996, 7, 437-448. | 0.8 | 96 |
| 290 | Treatment of Hodgkin's Disease: The Swedish National Care Programme Experience. Leukemia and Lymphoma, 1996, 21, 71-78. | 0.6 | 34 |
| 291 | Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Annals of Oncology, 1996, 7, 593-600. | 0.6 | 696 |
| 292 | Radiotherapy in Addition to Radical Surgery in Rectal Cancer. Acta OncolÃ³gica, 1995, 34, 565-570. | 0.8 | 18 |
| 293 | Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Annals of Oncology, 1995, 6, 267-274. | 0.6 | 141 |
| 294 | Selective sensitivity of solid tumors to suramin in primary cultures of tumor cells from patients. International Journal of Cancer, 1995, 63, 356-360. | 2.3 | 11 |
| 295 | A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. Cancer, 1994, 73, 445-454. | 2.0 | 41 |
| 296 | Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. Cancer, 1994, 73, 556-562. | 2.0 | 133 |
| 297 | Detection of tumor-specific cytotoxic drug activityIN VITRO using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. International Journal of Cancer, 1994, 56, 715-720. | 2.3 | 71 |
| 298 | Diagnostics of Malignant Lymphomas with Ultrasound Guided 1.2 MM Biopsy-Gun. Acta OncolÃ³gica, 1994, 33, 33-37. | 0.8 | 11 |
| 299 | Treatment of early and intermediate stages of supradiaphragmatic Hodgkin's disease: The Swedish National Care Programme Experience. Annals of Oncology, 1994, 5, 809-816. | 0.6 | 19 |
| 300 | Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. , 1994, 73, 556. | | 1 |
| 301 | Infiltration of eosinophils in Hodgkin's disease involved lymph nodes predicts prognosis. Hematological Oncology, 1993, 11, 187-193. | 0.8 | 79 |
| 302 | Pre-chemotherapy nervousness as a marker for anticipatory nausea: A case of a non-causal predictor. Psycho-Oncology, 1993, 2, 33-41. | 1.0 | 3 |
| 303 | Preoperative or postoperative irradiation in adenocarcinoma of the rectum. Diseases of the Colon and Rectum, 1993, 36, 564-572. | 0.7 | 482 |
| 304 | Radioimmunolocalization of Hepatic Metastases and Subcutaneous Xenografts from a Human Colonic Cancer: In the Nude Rat: Aspects of Tumour Implantation Site and Mode of Antibody Administration. Acta OncolÃ³gica, 1993, 32, 877-885. | 0.8 | 4 |
| 305 | A Comprehensive Cancer Care Project to Improve the Overall Situation of Patients Receiving Intensive Chemotherapy. Journal of Psychosocial Oncology, 1993, 11, 17-40. | 0.6 | 17 |
| 306 | Biochemical modulation of 5-fluorouracil: A randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. Annals of Oncology, 1993, 4, 235-240. | 0.6 | 67 |

| # | Article | IF | Citations |
|---|---|---|---|
| 307 | The Value of Adjuvant Therapy after Radical Surgery for Colorectal Cancer. Annals of Medicine, 1992, 24, 9-14. | 1.5 | 6 |
| 308 | Improved Care of Patients with Small Cell Lung Cancer Nutritional and Quality of Life Aspects. Acta OncolÃ³gica, 1992, 31, 823-831. | 0.8 | 14 |
| 309 | General Condition of Asymptomatic Patients with Advanced Colorectal Cancer Receiving Palliative Chemotherapy: A longitudinal study. Acta OncolÃ³gica, 1992, 31, 645-651. | 0.8 | 35 |
| 310 | Lymphoma Incidence in a Swedish County During 1969â€“1987. Acta OncolÃ³gica, 1992, 31, 275-282. | 0.8 | 30 |
| 311 | Prognostic significance of flow cytometry studies in B-cell non-hodgkin lymphoma. Hematological Oncology, 1990, 8, 1-12. | 0.8 | 47 |
| 312 | Immunophenotype analysis of Bâ€CLL lymphoma and immunocytoma. Apmis, 1989, 97, 1025-1032. | 0.9 | 5 |
| 313 | Primarily asymptomatic lowâ€grade nonâ€Hodgkin lymphomas: Prediction of symptomâ€free survival and total survival. European Journal of Haematology, 1989, 43, 332-338. | 1.1 | 14 |
| 314 | Extracellular matrices in multicellular spheroids of human glioma origin: Increased incorporation of proteoglycans and flbronectin as compared to monolayer cultures. Apmis, 1988, 96, 433-444. | 0.9 | 41 |
| 315 | Cytostatic Drug Therapy in Disseminated Colorectal Cancer. Scandinavian Journal of Gastroenterology, 1988, 23, 181-189. | 0.6 | 2 |
| 316 | Prognostic relevance of serumâ€markers in relation to histopathology, stage and initial symptoms in advanced lowâ€grade nonâ€Hodgkin lymphomas. European Journal of Haematology, 1988, 40, 289-298. | 1.1 | 22 |
| 317 | A clinical study of CA-50 as a tumour marker for monitoring of colorectal cancer. Medical Oncology and Tumor Pharmacotherapy, 1988, 5, 165-71. | 1.0 | 6 |
| 318 | Radiation therapy in upper GI tract tumours. Acta Chirurgica Scandinavica Supplementum, 1988, 541, 32-8. | 0.1 | 0 |
| 319 | DNA CONTENT IN CARCINOMA OF THE RECTUM AND RECTOSIGMOID. Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section A, Pathology, 1985, 93A, 277-284. | 0.3 | 3 |
| 320 | Local recurrences after surgical treatment for rectal carcinoma. Acta Chirurgica Scandinavica, 1984, 150, 331-5. | 0.2 | 94 |
| 321 | Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer. Oncotarget, 0, 7, 41948-41958. | 0.8 | 30 |